Why Cytek Biosciences, Inc.’s (CTKB) Stock Is Up 5.91%
As of Thursday, November 19, Cytek Biosciences, Inc.’s CTKB share price has surged by 5.91%, which has investors questioning if this is right time to sell.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Jenna Brashear
Cynthia McLaughlin
Cynthia McLaughlin
Cynthia McLaughlin
| Share Statistics | CTKB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $826.6 | $3,419.7 | 44% |
|
| Shares Out (Mil) | 130.4 | 105.4 | 67% |
|
| Institutional Ownership | 87.2% | 89.4% | 54% |
|
| Float (Mil) | 105.8 | 77.0 | 61% |
|
| Beta | 1.14 | 1.16 | 67% |
|
| Avg Daily Volume (000s) | 1,305 | 1,070 | 74% |
|
| Price Change (52-week) |
14.3% | 82.9% | 65% |
|
| Growth | CTKB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 16.8% | 7.5% | 76% |
|
| Net Income (5yr) | (40.3%) | (12.1%) | 9% |
|
| EPS (5yr) | (48.5%) | 2.1% | 4 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (14.9%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($0.070) | ($0.287) | ($0.183) | |
| Month Ago EPS | na | ($0.120) | $0.070 | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | na | ($0.120) | $0.070 | |
| Year/Year Chg | 48.9% | (44.9%) | (78.9%) | |
| Financials | CTKB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $208 | $811 | 32% |
|
| Net Income (TTM) (Mil) | ($81) | ($19) | 12% |
|
| EPS (TTM) | ($0.629) | ($0.300) | 25% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | $52 | 23% |
|
| Net Cash Flow (TTM) (Mil) | ($26) | $3 | 26% |
|
| Long-Term Debt (Q1) (Mil) | $13 | $252 | 30% |
|
| Enterprise Value (Q1) (Mil) | $531 | $3,486 | 35% |
|
| Valuation | CTKB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.57 | 3.21 | 65% |
|
| P/E | na | 34.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 6.5 | na |
|
| Ratios | CTKB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 53.4% | 47.8% | 66% |
|
| Net Margin | (39.1%) | (3.0%) | 13% |
|
| ROA | (17.3%) | (5.4%) | 21% |
|
| ROE | (23.2%) | (5.2%) | 22% |
|
| Liabilities to Assets | 28.0% | 41.5% | 19% |
|
| F-Score | 3 | 5 | 18% |
|
Cytek Biosciences, Inc. did not pass any screens on 11/19/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors